Calcium Dobesilate

Anatomic Therapeutic Chemical Classification

• C05BX01

ATC Code (veterinary)

• QC05BX01

Uses and Administration

Drug Profile

Calcium dobesilate is claimed to reduce capillary permeability and has been used in various peripheral circulatory disorders including diabetic retinopathy and haemorrhoids ( Refer to ). Gastrointestinal disturbances have occurred with its use, and there are also reports of hypersensitivity reactions.

Calcium dobesilate is given orally in usual doses of 0.5 to 1.5 g daily in divided doses. It is also given rectally for haemorrhoids and is an ingredient of some preparations given for various skin disorders.

(last reviewed 2010-09-02; last modified 2008-08-05)

Adverse effects

Agranulocytosis has been reported^1-3 in a few patients after treatment with calcium dobesilate, and in 2 cases recurred on rechallenge.^1,2However, a later review⁴ of the safety profile of calcium dobesilate concluded that the overall risk of adverse effects was low with the most prominent symptoms being fever, arthralgias, and gastrointestinal disturbances. Reports of agranulocytosis were rare and the authors concluded that there may have been methodological bias in previous assessments of risk.

(last reviewed 2010-09-02; last modified 2006-07-20)

References

1. Kulessa W, et al.. Wiederholte Agranulozytose nach Einnahme von Calciumdobesilat.Dtsch Med Wochenschr. 1992; 117: 372–4. PubMed

2. Cladera Serra A, et al.. Agranulocitosis inducida por dobesilato calcico.Med Clin (Barc). 1995; 105: 558–9. PubMed

3. García Benayas E, et al.. Calcium dobesilate-induced agranulocytosis.Pharm World Sci. 1997; 19: 251–2. PubMed

4. Allain H, et al.. Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids.Drug Safety. 2004; 27: 649–60. PubMed

Uses

Although there have been reports from small studies of a positive effect of calcium dobesilate in patients with diabetic retinopathy, the conclusion from a large multicentre, randomised, double-blind, placebo-controlled study was that it neither prevented the occurrence of nor reduced the probability of developing clinically significant macular oedema during the 5-year follow-up period in patients with type 2 diabetes mellitus and mild-to-moderate non-proliferative diabetic retinopathy.¹

(last reviewed 2010-09-02; last modified 2010-05-15)

References

1. Haritoglou C, et al.. Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebo-controlled, multicentre trial.Lancet. 2009; 373: 1364–71. PubMed

Preparations: Single-Ingredient

The following preparations list represents a compilation of all available salt forms or related substances for this drug product.

The symbol ¤ denotes a preparation which is discontinued or no longer actively marketed.

ARGENTINA: Doxium; Duflemina; Eflevar;AUSTRIA: Doxium; Vasactin¤;BELGIUM: Doxium¤;BRAZIL: Dobeven; Doxium¤;CHILE: Doxium;CHINA: An Duo Ming (安多明); Dashiming (达士明); Doxium (导升明); Hao Chang (昊畅); Keyuan (可元); Li Bei Si (利倍思); Medoril (美多瑞);CZECH REPUBLIC: Danium¤; Dobica; Doxium;FRANCE: Doxium;GERMANY: Dexium¤; Dobica¤;GREECE: Difilina¤; Doxytrex; Nugatex¤; Stifarol¤;HONG KONG: Dobesifar¤; Doxium;HUNGARY: Doxilek; Doxium;INDIA: Cabisyl; Caldob; Cocalate; DBS; Dobesil; Dobest; Dobilet; Dobkair; Dosil; Doxium; Eflo; Mobium;ITALY: Dobesifar¤; Doxium;MALAYSIA: Doxium;MEXICO: Doxium;PHILIPPINES: Doxium;POLAND: Dobenox; Doxium; Galvenox;PORTUGAL: Doxi-Om; Doxivenil;RUSSIAN FEDERATION: Doxi-Hem (Докси-хем);SOUTH AFRICA: Doxium¤;SPAIN: Doxium;SWITZERLAND: Doxium;TURKEY: Docalix; Doxium; Modet;VENEZUELA: Deoxical; Doxium;

Preparations: Multi-Ingredient

The following preparations list represents a compilation of all available salt forms or related substances for this drug product.

The symbol ¤ denotes a preparation which is discontinued or no longer actively marketed.

ARGENTINA: Vasodual¤;AUSTRIA: Doxiproct mit Dexamethason¤; Doxiproct¤;BRAZIL: Proctium¤;CZECH REPUBLIC: Danium Compositum¤; Dobexil Plus¤; Dobexil; Doxiproct Plus; Doxiproct; Doxivenil¤;HUNGARY: Doxiproct Plus; Doxiproct; Doxivenil¤;ITALY: Doxiproct¤; Doxiproct; Doxivenil¤;MEXICO: Doxiproct Plus; Doxiproct¤; Novoben; Vasculflow;PORTUGAL: Doxiproct Plus; Doxiproct;SPAIN: Acnisdin Retinoico¤; Acnisdin¤; Ederal¤; Proctium¤;SWITZERLAND: Doxiproct Plus; Doxiproct; Doxivenil¤;VENEZUELA: Doxivenil;

Last Updated 1/21/20